CJC-1295 w/ DAC (2mg)
Table of Contents
Quickstart Highlights
CJC-1295 DAC (2 mg Vial) is a long-acting GHRH analog that forms an albumin bond in vivo, extending its half-life to ~6–8 days and enabling once-weekly research dosing schedules. This page provides an educational reconstitution and dosing unit guide for a 2 mg vial.
- Reconstitute : 1.0 mL bacteriostatic water → 2 mg/mL (2,000 mcg/mL)
- Once-weekly schedule : supported by pharmacokinetics (t½ ≈ 6–8 days)
- Standard approach : 1.0 mg (50 units / 0.50 mL) once weekly
- Advanced approach : 2.0 mg (100 units / 1.00 mL) once weekly
- Storage : Lyophilized frozen; reconstituted refrigerated (details below)
Product ID : 1043 :
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing units
Reconstitution (1.0 mL = 2 mg/mL)
- Draw 1.0 mL of bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe.
- Inject slowly down the vial wall; gently swirl (avoid vigorous shaking).
- Label the vial with date and concentration (2 mg/mL).
- Refrigerate reconstituted solution at 2–8 °C (36–46 °F), protected from light.
Why 1.0 mL? It yields practical once-weekly injection volumes (≤1.0 mL). Using larger volumes (e.g., 2–3 mL) would increase “units” but may require >1 mL per injection at higher weekly doses. Do not exceed 3 mL per vial.
Standard / Gradual Approach (1.0 mL = 2 mg/mL)
| PHASE | DOSAGE (MCG) | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–8 | 1.0 mg once weekly | 50 units (0.50 mL) |
Frequency: Inject 1× per week subcutaneously. One 2 mg vial provides two 1 mg injections (≈2 weeks).
Advanced / Aggressive Approach (1.0 mL = 2 mg/mL)
| PHASE | DOSAGE (MCG) | UNITS (PER INJECTION) |
|---|---|---|
| Weeks 1–8 | 2.0 mg once weekly | 100 units (1.00 mL) |
Frequency: Inject 1× per week subcutaneously. One 2 mg vial provides one 2 mg injection (≈1 week).
Tip: If your syringes are <1 mL capacity, split the 2.0 mg dose into two back-to-back injections to maintain accuracy.
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Slowly inject the water to reduce foaming and peptide agitation.
- Gently roll/swirl the vial—no vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Protocol Overview
- Goal (research) : Model GH/IGF-1 axis stimulation using a long-acting GHRH analog
- Schedule : Once weekly subcutaneous dosing for 8–12 weeks (extendable per protocol)
- Dose Range:: 1.0–2.0 mg weekly (see unit tables above)
- Reconstitution : 1.0 mL → 2 mg/mL; practical 25–100 insulin units per injection
- Storage : Lyophilized frozen; reconstituted refrigerated (details below)
Dosing Protocol
- Standard : 1.0 mg (50 units / 0.50 mL) once weekly
- Advanced : 2.0 mg (100 units / 1.00 mL) once weekly
- Timing : Any consistent weekly time; separate from meals if specified by your protocol
- Documentation : Record lot, concentration, date/time, site, and volume for each injection
Storage Instructions
- Lyophilized : Freeze for long-term storage (≤ −20 °C / −4 °F ideally); short-term at 2–8 °C / 36–46 °F.
- Reconstituted : Refrigerate at 2–8 °C / 36–46 °F; avoid repeated freeze–thaw; aliquot if needed.
- Allow the vial to reach room temp before opening to reduce moisture uptake; protect from light.
Suppilies Needed
Estimates for 8–16 week research cycles.
- Peptide Vials (2 mg each): :
• Standard 1 mg/wk → 8 wks ≈ 4 vials; 12 wks ≈ 6; 16 wks ≈ 8
• Advanced 2 mg/wk → 8 wks ≈ 8 vials; 12 wks ≈ 12; 16 wks ≈ 16
- Insulin Syringes : 8 / 12 / 16 (match weekly injections)
- Bacteriostatic Water : 10 mL bottle(s): 8–12 wks = 1×; 16 wks (advanced) = 2×
- Alcohol Swabs: 1 box
Important Notes
- Use new, sterile syringes; do not reuse needles or share multi-dose vials between subjects.
- Rotate injection sites (abdomen, thigh, etc.) and clean the stopper and skin with alcohol.
- Monitor and document observations; discontinue per protocol if unexpected reactions occur.
- Research Use Only : Not for human or veterinary use. This page is for educational purposes only.
How This Works
CJC-1295 DAC is a modified GHRH(1-29) analog that bioconjugates to albumin (Cys-34), prolonging circulation time. In healthy adults, single doses produced 2–10× GH increases for ~6 days and IGF-1 elevation for ~9–11 days; multiple doses sustained IGF-1 above baseline for up to 28 days, while preserving GH pulsatility.
Potential Research Observations & Considerations
- Intended effect : Dose-dependent increases in GH and IGF-1
- Commonly reported events : Injection-site reactions, flushing, headache, transient nausea
- Metabolic caution : GH axis activation can influence glucose/insulin dynamics; monitor per protocol
Lab & Handling Practices
- Define sampling windows (e.g., pre-/post-dose GH/IGF-1 timepoints) before starting
- Standardize dosing relative to meals and time of day to reduce variability
- Document storage conditions, batch/lot, and reconstitution details for QC traceability
Injection Technique (Educational)
- Use aseptic technique; a new needle & syringe for each injection.
- Subcutaneous angle: 45–90°, inject slowly; dispose in sharps container.
- Do not exceed syringe capacity; split doses if volume > 1 mL.
Recommended Source
We recommend Go Alpha Labs for high-purity CJC-1295 DAC (2 mg).
Why Go Alpha Labs?
- Independent lab testing with ≥99% purity
- ISO-aligned quality control for reliable research
- Consistent lots and transparent COA support
Compliance Notice:
For Research Use Only.